I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation
*Corresponding author: Yury S. Milovanov, PhD, ScD, Leading Researcher of the Nephrology Department, I.M. Sechenov First Moscow State Medical University, 11, Rossolimo st., building 4, 119992, Moscow, Russian Federation.Tel: 7-903-5205122 (mobile). E-mail: email@example.com
Published: September 24, 2013
The aim of the study was to evaluate the effect of a low protein diet (LPD) balanced with essential amino acids (EAA) / keto acid analogs (KAA) and protein “SUPRO-XT 219D” in the composition of the high-energy nutrient blend (HENB) for slow down of renal failure in patients in the pre-dialysis stage of chronic kidney disease (CKD) induced by systemic autoimmune diseases (SAD).
Material and Methods: In this study, 46 patients (35 with systemic lupus erythematosus and 15 with various forms of systemic vasculitis) with CKD in stages 3-4 were randomized into three groups. Group 1 (18 patients: 10 with CKD stage 3 and 8 with CKD stage 4) was given LPD (0.6 g protein per kg of body weight per day comprising 0.3 g of vegetable protein and 0.3 g of animal protein) balanced with EAA/KAA (Diet #1); Group 2 (18 patients: 9 with CKD stage 3 and 9 with CKD stage 4) was given the same LPD, but with an increased vegetable protein content (purified soy protein SUPRO-XT 219D) up to 0.4 g/kg/day in the composition of HENB (Diet #2); Group 3, comparison group, (10 patients: 7 with CKD stage 3 and 3 with CKD stage 4) was given a free diet (Diet #3) based on the patient’s personal preferences. Both options of LPD were offered to all the patients of Groups 1 and 2 regardless of their baseline nutritional status (NS). The duration of the observation was 24-48 months. The NS was evaluated based on the bioelectrical impedance analysis. The protein and calorie intake was calculated from the 3-day food diary.
Results: Among the 46 patients with CKD stages 3-4, NS impairment was detected in almost half the patients (45.7%). Both forms of LPD were well tolerated. The correction of the nutritive impairment was achieved in patients with baseline impaired NS; the remaining patients of Groups 1 and 2 demonstrated the safety of NS against LPD. At the same time, among Group 3 patients, during the progression of renal disorders, the NS rate was observed to increase by 1.5 times (from 40% to 60%). Slowing down the glomerular filtration rate (GFR) decline was observed in the patients treated with LPD for at least a year, which was more significant in the subgroup fed with the increased quota of vegetable protein SUPRO-XT 219D.
Conclusion: Early restriction (on pre-dialysis stage) of the protein intake (0.6 g/kg/day) supplemented with HENB and EAA/KAA revealed a positive effect on the NS of CKD patients and was found to be able to slow down the GFR decline.
1. National Kidney Foundation. K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (2 Suppl 1):S1-266.
2. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet on Renal Disease Study Group. N Engl J Med 1994; 330(1):877-84.
3. Kasiske BL, Lacatua JD, Ma JZ, Louis TA. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis 1998; 31(6):954-61.
4. Nikolaev AY, Milovanov YuS. Treatment of the chronic renal failure: A guide for physicians. M: Medical news agency; 2011. [Guide in Russian].
5. Zakar G. The effect of ketoacid supplement on the course of cronic renal failure and nutritional parameters in predialysis patients and patients on regular dialysis theraphy: the Hungarian ketosteril cohort study. Wien. Klin. Wschr. 2001; 113: S686-S694
6. Walser M, Hill SB, Ward L, Magder L. A crossover comparison of progression of chronic renal failure: ketoacids versus amino acids. Kidney Int 1993; 43(4):933-9.
7. Ermolenko VM, Kozlov TA, Mikhailova N. The role of the low-protein diet to slow the progression of chronic renal failure. Nephrology and Dialysis 2006; 4:310-20. [Article in Russian].
8. Levey AS, Adler S, Caggiula AW, England BK, Grerne T, Hunsicker LG, et al. Effects of dietary protein restriction on the progression of the moderate renal disease in the Modification of Diet on Renal Disease Study. J Am Soc Nephrol 1996; 7(12):2616-26.
9. Teschan PE, Beck GJ, Dwyer JT, Greene T, Klahr S, Levey AS, et al. Effect of ketoacid-aminoacid-supplemented very low protein diet on the progression of advanced renal disease: a reanalysis of the MDRD feasibility study. Clin Nephrol 1998; 50(5):273-83.
10. Fouque D, Wang P, Laville M, Boissel JP. Low-protein diets delay end- stage renal disease in non- diabetic adults with chronic renal failure. Nephrol Dial Transplant 2000; 15(12):1986-92.
11. Laouari D., Lleinknecht C., Broyer M. Use of keto analogs of amino acids in chronic renal insufficiency. Nephrologie 1986; 7(4):133-6. [Article in French].
12. Milovanov YS, Kozlovskaya LV, Milovanova LYu. Nephroprotective role of early correction of nutritional status in patients with chronic kidney disease in the predialysis phase. Ter arkh 2008; 6:56-60. [Article in Russian].
13. Mukhin N, Tareeva IE, Shilov EM. Diagnosis and treatment of kidney diseases. M.: GEOTAR-MED; 2002. [Book in Russian].
14. Bergesio F, Monzani G, Guasparini A, Ciuti R, Gallucci M, Cristofano C, et al. Cardiovascular risk factors in severe chronic renal failure: the role of dietary treatment. Clin Nephrol 2005; 64(2):103-12.
15. Mitch WE, Clark AS. Specificity of the effects of leucine and its metabolites on protein degradation in skeletal muscle. Biochem J. 1984; 222(3):579-86.
16. Milovanov YuS, Lysenko LV, Milovanova LYu, Dobrosmyslov IA. Effect of low-protein diet balanced essential keto / amino acids and high-nutrient mixture on the progression of renal failure in predialysis chronic kidney disease caused by systemic diseases. Clinical Nephrol 2009; 1:62-6. [Article in Russian].
The fully formatted PDF version is available.
Int J Biomed. 2013; 3(3):184-187. © 2013 International Medical Research and Development Corporation. All rights reserved.